Apr 17, 2018

When does cognitive decline begin? A systematic review of change point studies on accelerated decline in cognitive and neurological outcomes preceding mild cognitive impairment, dementia, and death

Psychology and Aging
Justin E KarrGraciela Muniz-Terrera


Older adults who ultimately develop dementia experience accelerated cognitive decline long before diagnosis. A similar acceleration in cognitive decline occurs in the years before death as well. To evaluate preclinical and terminal cognitive decline, past researchers have incorporated change points in their analyses of longitudinal data, identifying point estimates of how many years prior to diagnosis or death that decline begins to accelerate. The current systematic review aimed to summarize the published literature on preclinical and terminal change points in relation to mild cognitive impairment (MCI), dementia, and death, identifying the order in which cognitive and neurological outcomes decline and factors that modify the onset and rate of decline. A systematic search protocol yielded 35 studies, describing 16 longitudinal cohorts, modeling change points for cognitive and neurological outcomes preceding MCI, dementia, or death. Change points for cognitive abilities ranged from 3-7 years prior to MCI diagnosis, 1-11 years prior to dementia diagnosis, and 3-15 years before death. No sequence of decline was observed preceding MCI or death, but the following sequence was tentatively accepted for Alzheimer's disease: verbal mem...Continue Reading

  • References
  • Citations7


  • We're still populating references for this paper, please check back later.
  • References
  • Citations7

Mentioned in this Paper

Senile Paranoid Dementia
Familial Alzheimer Disease (FAD)
Ability to Perform Cognitive Activity
Cessation of Life
Memory for Designs Test
Research Personnel
Executive Function
Alzheimer's Disease

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease is a chronic neurodegenerative disease. This feed focuses on early markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Alzheimer's disease (AD) is a chronic neurodegenerative disease. Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Related Papers

Journal of the International Neuropsychological Society : JINS
Diane B HowiesonJeffrey A Kaye
American Journal of Alzheimer's Disease and Other Dementias
Linda J ClarkWendy J Mack
Geriatrics & Gerontology International
Leandro FerreiraJosé Carlos Fernandes Galduróz
International Psychogeriatrics
Maddalena Bruscoli, Simon Lovestone
© 2020 Meta ULC. All rights reserved